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Background: Despite the availability of psychosocial evidence-based practices (EBPs), treatment and outcomes for
persons with mental disorders remain suboptimal. Replicating Effective Programs (REP), an effective implementation
strategy, still resulted in less than half of sites using an EBP. The primary aim of this cluster randomized trial is to
determine, among sites not initially responding to REP, the effect of adaptive implementation strategies that begin
with an External Facilitator (EF) or with an External Facilitator plus an Internal Facilitator (IF) on improved EBP use
and patient outcomes in 12 months.
Methods/Design: This study employs a sequential multiple assignment randomized trial (SMART) design to build
an adaptive implementation strategy. The EBP to be implemented is life goals (LG) for patients with mood
disorders across 80 community-based outpatient clinics (N = 1,600 patients) from different U.S. regions. Sites not
initially responding to REP (defined as <50% patients receiving ≥3 EBP sessions) will be randomized to receive
additional support from an EF or both EF/IF. Additionally, sites randomized to EF and still not responsive will be
randomized to continue with EF alone or to receive EF/IF. The EF provides technical expertise in adapting LG in
routine practice, whereas the on-site IF has direct reporting relationships to site leadership to support LG use in
routine practice. The primary outcome is mental health-related quality of life; secondary outcomes include receipt
of LG sessions, mood symptoms, implementation costs, and organizational change.
Discussion: This study design will determine whether an off-site EF alone versus the addition of an on-site IF
improves EBP uptake and patient outcomes among sites that do not respond initially to REP. It will also examine
the value of delaying the provision of EF/IF for sites that continue to not respond despite EF.
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It can take years to translate evidence-based practices
(EBPs) into community-based settings [1]. This research-
to-practice gap is especially pronounced for psychosocial
EBPs for mood disorders (depression, bipolar disorders),
which represent the top ten causes of disability according
to the World Health Organization. Mood disorders are
associated with significant functional impairment, high
medical costs, and preventable mortality [2,3]. For many
patients, pharmacotherapy is not enough to improve out-
comes, with psychosocial treatments in addition to pharma-
cotherapy recommended [4-7].
Despite the availability of psychosocial EBPs [1,4-8]
for mood disorders, they rarely get implemented and
sustained in community-based practices [9-11]. This is
primarily due to a lack of available strategies to help
providers embed the EBP into routine clinical work-
flows, and garner support from clinical and administra-
tive leadership on the EBP’s added value to the practice
[8,12-25]. As a result, outcomes for persons with mental
disorders remain suboptimal [12,26]. New healthcare ini-
tiatives including medical home models designed to im-
prove efficiency and value have not included specific
strategies to assist local providers in implementing EBPs
in routine care [27-29]. Moreover, up to 98% of patients
with mood disorders receive care from smaller clinical
practices, which may not have the tools to fully imple-
ment medical homes [30].
For EBPs to reach these patients, effective implemen-
tation strategies are needed [31-34]. Implementation
strategies that have been highly specified, operational-
ized, and previously used to implement EBPs into usual
care settings include Replicating Effective Programs
(REP) [35]. REP primarily focuses on standardization of
the EBP implementation into routine care settings
through toolkit development and marketing, provider
training, and program assistance (Figure 1). Used suc-
cessfully to improve the uptake of brief HIV interven-
tions [36-39], REP is a low-intensity intervention with
minimal costs for sites. However, when applied to the
implementation of a psychosocial EBP for mood disor-
ders, REP resulted in less than half of sites implementing
the EBP [40].Figure 1 Replicating Effective Programs (REP) and Internal/External FRecognizing the need for more intensive implementa-
tion strategies that leverage local provider initiative and
outside expertise [41], REP was enhanced to include
Facilitation [40,41]. Two Facilitation roles evolved: an Ex-
ternal Facilitator (EF), employed from outside the local
site, and an Internal Facilitator (IF), employed at each of
the local sites. EFs are situated at a central location and
provide technical expertise and program support in imple-
menting the EBP at the local site. In contrast, IFs have a
direct reporting relationship to site leadership and have
protected time to support providers in implementing EBPs
by helping them align the EBP activities with the priorities
of the clinic providers and local leadership.
A recent randomized controlled trial [40,42] of added
an External Facilitator (REP + EF) versus REP alone
found that among 88 sites not responding to REP, sites
randomized to receive REP + EF compared to sites con-
tinuing with REP were more likely to adopt the EBP
within 6 months (defined as percentage of patients re-
ceiving care management: 56% vs. 28%) [42]. This sug-
gests that while REP + EF led to increased uptake, a
more intensive, locally oriented implementation strategy
(e.g., Internal Facilitation) might be needed for EBP up-
take in sites that do not fully implement the EBP. In a
different study, REP in combination with EF and IF
(REP + EF/IF) versus standard REP alone improved
adoption and fidelity to a mood disorder EBP [43,44],
underscoring the promise of REP + EF/IF.
However, because IF requires additional time commit-
ment from sites, and not all sites may need IF, an adaptive
implementation strategy approach is a more practical design.
In contrast to measuring implementation non-response
(or correlates of it) and not using it to guide improved im-
plementation and outcomes, in adaptive implementation
strategies, implementation interventions are augmented
in direct response to limited adoption of EBPs among
specific sites based on circumstances that may not be ob-
servable at baseline. This study addresses key scientific
questions that need to be answered in order to develop
an effective adaptive implementation strategy. Notably,
among sites not responding to REP (i.e., not adopting
the EBP), is it best to augment with REP + EF/IF or with
REP + EF, or is it best to delay the provision of REP + EF/acilitation (EF/IF).
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REP + EF augmentation?
Aims and objectives
The overarching goal of this study is to build the most ef-
fective adaptive implementation strategy involving two
cutting-edge implementation strategies (REP and Facilita-
tion) to improve practice-level uptake of EBPs and patient
outcomes. The EBP, life goals (LG), is an evidence-based
psychosocial treatment delivered in six individual or group
sessions that was shown in seven randomized controlled
trials to improve mental and physical health outcomes
among patients with mood disorders [44-49]. We will use a
sequential multiple assignment randomized trial (SMART)
[50,51] design to build the adaptive intervention in which
data on early response or non-response to REP will be used
to determine the next implementation strategy.
Primary study aim
The primary aim of this study is to determine in a SMART
implementation trial, among patients with mood disorders
in sites that do not exhibit response to REP alone after
6 months (i.e., <50% patients receive ≥3 LG sessions), the
effect of adding an External and Internal Facilitator (REP +
EF/IF) versus REP + EF on patient-level changes in mental
health-related quality of life (MH-QOL; primary outcome),
receipt of LG sessions, mood symptoms, implementation
costs and organizational change (secondary outcomes)
from month 6 to month 24.
Secondary aim 1
The first secondary aim is to determine, among REP +
EF sites that continue to exhibit non-response after an
additional 6 months, the effect of continuing REP + EF
vs. REP + EF/IF on patient-level changes in the primary
and secondary outcomes from month 12 to month 24.
Secondary aim 2
The second secondary aim is to estimate the site-level
costs of REP + EF/IF compared to REP + EF.
Secondary aim 3
The third secondary aim is to describe the implementation
of EF and EF/IF at the site level, including interaction be-
tween the two roles and the specific strategies EFs and IFs
use to facilitate LG uptake across different sites.
The result of this current SMART study will be an op-
timized, adaptive implementation strategy that that
could be applied to healthcare systems to improve out-
comes for patients with mental disorders.
Methods
This cluster randomized SMART implementation trial
(Figure 2) involves community-based clinics (sites) fromMichigan (MI) and Colorado (CO) that care for persons
with mood disorders (depression or bipolar disorders).
This study was reviewed and approved the local institu-
tional review boards.
Setting
Eighty community-based mental health or primary care
clinics from the two states will be recruited to partici-
pate in the study based on lists of primary care and
community mental health programs available from state
organizations. Since the EBP to be implemented (LG)
has been shown to be effective in improving outcomes
across different settings (primary care, community men-
tal health) [45-47,49,52], a diverse array of sites will be
recruited to maximize study generalizability.
Sites
Site inclusion criteria include the following:
1. Community-based mental health or primary care
clinic located in Michigan or Colorado with at least
100 unique patients diagnosed with or treated for
mood disorders.
2. Availability of a bachelor’s- or master’s-level
healthcare provider with a mental health background
and experience with implementing individual or group
sessions (core modality of LG) who can be trained to
provide LG to up to 20 adult patients with mood
disorders in the clinic in a 1-year period.
3. Availability of an employee at the site with direct
reporting authority to the leadership of the site or
parent practice organization who could serve as
potential internal facilitator.
Study design flow
Primary care or mental health outpatient clinics con-
firming eligibility using a standard organizational assess-
ment and agreeing to participate will initially be offered
REP for 6 months in order to implement LG (Figure 2).
Based on previous research [53] and preliminary data, it
is expected that after 6 months of REP, at least 80% of
sites will be non-responsive to REP. The primary focus
of the randomized comparisons in this study are sites
that are initially non-responsive to REP, defined based
on our preliminary studies as <50% of previously identi-
fied patients receiving at least three LG sessions (≥3 out
of 6) to achieve minimum clinically significant results
(85–89). Although not part of the primary randomized
comparisons, sites that are responsive at 6 months will
continue to be followed and outcomes will be assessed.
Patients within sites
The unit of analysis is LG eligible patients within sites
who are diagnosed with or treated for mood disorders.
Figure 2 SMART trial design of REP combined with External (EF, REP + EF) and Internal Facilitation (IF, REP + EF/IF).
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of REP, i.e., prior to site-level randomization (see step 1
of REP below). Patient-level primary and secondary out-
comes will be assessed by independent evaluators (i.e.,
study associates who are not aware of the assignment to
REP + EF or REP + EF/IF) across all sites prior to identi-
fying site response/non-response status at month 6,
prior to identifying site response/non-response status at
month 12, and at months 18 and 24.
Site randomization
The unit of intervention (randomization) is the site. Sites
that are not responding to REP at month 6 will be
randomized 1:1 by the study data analyst to receive
additional External Facilitation (REP + EF) or External
plus Internal Facilitation (REP + EF/IF). After another
6 months (at month 12), (i) REP + EF sites that are still
non-responsive (defined as <50% patients receiving ≥3
life goals sessions) will be randomized 1:1 to either con-
tinue REP + EF or augmentation with IF (REP + EF/IF)
for an additional 12 months, and (ii) intervention will be
discontinued for sites that are responsive. The month 6
randomization will be stratified by state, practice type
(primary care or mental health site) [54,55], and by site-
average baseline MH-QOL (e.g., low (<40) vs. high
(≥40)) at baseline. The month 12 randomization will be
stratified by state, practice type, and site-average MH-
QOL at month 12. This will ensure that intervention
groups are balanced for site variables that may correlate
highly with outcomes. The study analyst will generate
the stratified permuted-block random allocation lists
(blocks of size 2, 4, and 6) using a computer program
such as PROC PLAN in SAS. Sites are expected to be-
come eligible and accrue in groups of 6–12 (staggeredentry). A site is considered randomized once the study
analyst informs the study coordinator of each site’s ran-
dom assignment.
Evidence-based practice to be implemented
LG [44-49,52] is a psychosocial intervention for mood
disorders delivered in six individual or group sessions
(Table 1). Based on social cognitive theory [56-58], LG
encourages active discussions focused on individuals’
personal goals that are aligned with healthy behavior
change and symptom management strategies. LG was
chosen to be the EBP to implement because mood disor-
ders are common in both community-based primary
care and mental health clinics [59,60], are considered to
be high-priority populations based on input from com-
munity partners, and because LG was shown to improve
outcomes including mental health-related quality of
life in this group [45-47,49,52]. Compared to usual care,
LG improved outcomes among a cross-diagnosis sample
of community-based outpatients with mood disorders
[45-49,52], notably a four-point increase in mental and
physical health-related quality of life scores based on the
SF-12 (e.g., Cohen’s D = .36) [45,46,49]. LG has been
shown to be equally effective in patients with co-occurring
substance use and medical comorbidities [46,47,49,52,61].
Community-based providers helped to adapt LG [46-48],
but as with many psychosocial EBPs, have not been widely
implemented in smaller practices [62].
Implementation strategies
REP
All sites will receive REP (Table 2) in the first 6 months.
REP is based on the Centers for Disease Control and
Prevention’s (CDC’s) Research to Practice Framework
Table 1 Components of the life goals program
Component Description/core concepts across all
self-management sessions
Self-management sessions A minimum of six individual sessions
lasting ~50 min each or four group
sessions lasting ~90 min each focused
on active discussions around personal
goals, mental health symptoms, stigma,
and health behaviors
Values Explore personal values and their
relationship to health change behavior;
also explore types of stigma and ways
to overcome stigma
Collaborative care Identify ways to strengthen relationships
and participation in healthcare, explore
the importance of coming prepared to
medical visits, and identify ways to
ensure true collaboration is occurring
to support optimal health outcomes.
Self-monitoring Discuss the importance of
measurement-based care and develop
a meaningful self-monitoring plan for
identified mental or physical health
condition (i.e., PHQ-9, GAD-7, sleep log,
food tracking)
Symptom profile Create a personal symptom profile for
a specific mental health condition with
a focus on identifying early warning
signs and ways to use this knowledge
to bolster self-management skills
Triggers Identify positive and negative,
preventable and inevitable triggers
and ways to better prepare for and
manage these triggers
Cost/benefit analysis of
responses
Explore previous responses to
psychiatric symptoms and link
responses to personal values and
behavior change goals
Life goals Create SMART goals, problem-solve
barriers, and ensure personal goals
are in line with identified values
Care management At least monthly (for 6 months)
individualized follow-up contacts to
support lessons learned; contacts work
to problem-solve barriers to
health-behavior goals and provide
additional support for mental health
issues interfering with goal attainment
Provider decision support Knowledge and availability of best
practice treatments for mental and
physical health conditions either
in-house or via consult
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LG program by study investigators, package dissemination
and training by an off-site trainer, as-needed program sup-
port in using LG (program assistance), and LG uptake
monitoring for up to 6 months [35,44]. The theories
underlying REP [64,65] include Rogers’ Diffusion of Inno-
vations [36] and Social Learning Theory [66]. For this
study, REP includes the following components:Step 1: marketing and dissemination of LG package,
in-service, and patient selection
Regional in-services will first be provided by study inves-
tigators who will give an overview of LG including the
evidence, and details on how to implement LG in their
setting. Each site will designate at least one provider
with a mental health background to implement LG (“LG
provider”), and the LG package will be disseminated by
the REP trainer to these providers.
The LG REP package includes all of the components
needed to implement LG, including the LG provider
manual; a protocol for identifying patients to enroll in
LG; LG session scripts and focus points covered in each
session in a semi-directed fashion; the registry template
for tracking enrolled patients’ progress in LG session-
based personal goals, symptoms, and health behavior
change; scripts for follow-up calls, patient workbooks,
and an implementation manual describing logistics (e.g.,
identifying rooms if group sessions are used, identifying
patients for LG, medical record templates for LG ses-
sions, billing codes). Because LG effectiveness was
already demonstrated in patients with mood disorders
and that the primary goal of the study is to promote LG
implementation, LG providers will identify and offer LG
to patients at their site with mood disorders based on
guidance from the REP trainer [44,62]. The trainer will
work with LG providers to identify up to 30 patients
within a 3-month period who are appropriate for the LG
program using the following criteria that are included in
the registry template:
1. adults 21 years or older with a diagnosis and current
documentation of antidepressant or mood stabilizer
for a mood disorder (depression or bipolar disorder)
based on medical record review
2. not currently enrolled in residential treatment
3. can understand English and have no terminal illness
or cognitive impairment that precludes participation
in outpatient psychosocial treatment based on
confirmation by the treating clinician.
Assuming a 33% refusal or ineligibility rate [47], as
well as a potential 12-month attrition rate of around
20% from prior studies [47], LG providers will be expected
to identify and initially offer LG to 30 patients, assuming
20 will initially participate, with 16 to complete 12-month
follow-ups.
Step 2: REP LG training and provider competency
LG providers will undergo a 1-day training program that
has been provided to over 200 clinicians nationally
[44,67-69]. The LG trainer will first provide an orienta-
tion to the evidence behind LG and core elements and
then a step-by-step walk-through of LG components.
Table 2 Description of REP, REP + EF, and REP + EF/IF implementation strategies to enhance the uptake of the life goals
(LG) evidence-based practice
Implementation component REP REP + EF REP + EF/IF
REP (REP) All sites Randomize to
non-responding sites
Randomize to
non-responding sites
Step 1: Market LG, disseminate LG package. (a) Marketing
(pre-implementation): hold pre-implementation meetings
with site representatives to describe the benefits of LG
and identify potential LG providers and internal facilitators
(IF). (b) Dissemination: regional in-services to disseminate
LG implementation guide to providers, schedule trainings.
√ √ √
Step 2: Train site providers in LG. Conduct regionalized 8-h
training for LG providers covering LG session content and
delivery via LG website as well as patient tracking and
monitoring over time.
√ √ √
Step 3: As-needed program assistance and LG uptake
monitoring via secure web-based reporting sheets. Ad hoc
program support available by study program support assistant.
√ √ √
REP + External Facilitator (REP + EF)
Step 1: Initiation and benchmarking: EF contacts each LG
provider, works with LG provider to identify potential barriers
and facilitators to LG uptake from the LG provider’s perspective,
and sets measurable goals to uptake.
√ √
Step 2: Coaching: EF makes calls on a biweekly basis to site’s
LG providers to develop rapport and provide specific guidance
on overcoming barriers in implementing LG components by
aligning LG’s strengths with LG’s available influence at the site.
If needed, EF refers LG provider to study LG program
support assistant.
√ √
Step 3: Public recognition of “bright spots” (high-performing
sites): EF provides state-specific report on sites’ progress and
disseminates LG provider success stories.
√ √
REP + External and Internal Facilitator (REP + EF/IF)
Step 1: Initiation and benchmarking: EF contacts each LG
provider and holds call with LG provider and IF to give
background on LG, review potential barriers and facilitators
to LG uptake, and set measurable goals to LG uptake.
√
Step 2: Leveraging: IF meets with LG provider biweekly, identifies
local site priorities per leadership input, identifies other LG program
champions, and helps LG provider summarize and describe added
value of LG to leadership and site providers (e.g., consistency with
other initiatives, support from leadership).
√
Step 3: Coaching: IF, EF, and LG hold biweekly calls to develop
rapport; EF provides guidance to LG on overcoming specific
barriers to LG uptake by aligning LG’s strengths with LG’s available
influence at the site (EF), and IF aligns goals of LG provider with
existing site priorities, based on feedback from site leadership. If
needed, EF refers LG provider to study LG program support assistant.
√
Step 4: Ongoing marketing: IF, leadership, and LG provider summarize
progress and develop business and sustainability plans.
√
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follow-up contact procedures, as well as the standard-
ized criteria for identifying patients who are appropriate
for LG in routine practice. LG providers will break into
groups and practice each component.
After identifying eligible patients, LG providers will
make an initial contact to each patient, introduce the LG
program, and schedule in-person group or individual ses-
sions. Individual sessions typically last 50 min each, whilegroup sessions typically last around 90 min to allow for
additional discussions between group members. Partici-
pants can make up sessions over the phone if they are un-
able to make in-person sessions. In the sessions, the LG
provider will encourage active discussions that progres-
sively have participants identify a personal symptom pro-
file and triggers to the mood symptom or episode and
develop an activity plan for identifying warning signs of
symptoms and an activity plan for adopting a specific
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ness. Participants will be given a workbook with exercises
on behavior change goals, symptom assessments, and cop-
ing strategies. The LG provider will also make individual
contacts to patients after the end of the sessions on a
regular basis to review symptoms and behavior change.
LG providers are trained to handle patients with elevated
symptoms or suicidal ideation as part of their clinical
responsibilities.
Step 3: As-needed REP program assistance and LG
monitoring
The final phase of REP consists of as-needed program
assistance provided to LG clinicians who contact the LG
program support specialist. In addition, each LG pro-
vider is sent a standard monitoring form on a biweekly
basis for up to 6 months to have them record the num-
ber of patients approached and number receiving each
LG session. Monitoring forms will be used to assess
non-response across sites and will be corroborated based
on patient self-reported LG use from the follow-up sur-
veys (see data collection below). Sites will receive feedback
reports from the program support assistant that includes
performance on uptake measures (i.e., how many enrolled,
how many sessions) in comparison to other sites. Also,
sites will receive periodic (quarterly) newsletters about the
study progress.
Facilitation
The Facilitation implementation strategy will consist of
EF and IF (Table 2). Based on the Promoting Action on
Research Implementation in Health Services (PARiHS)
Framework [70-74], facilitation is defined as the process
of interactive problem solving and support that occurs
in the context of a recognized need for improvement
and a supportive interpersonal relationship [41,74].
LG providers from sites that are not responsive to REP
in 6 months after initiating LG at their site will be ran-
domized to receive REP + EF or REP + EF/IF. Sites re-
ceiving REP + EF will be contacted by the EF, who
resides off site. The EF will contact individual providers
from each site on a regular basis and conduct 1-hour
phone calls to provide guidance on implementing LG
components. Notably, the EF will be trained to identify
individual strengths of each LG provider and help lever-
age those strengths with available influence the LG pro-
vider has at the site. The EF will also set measurable
objectives in implementing LG (e.g., number of patients
completing at least one group session), review imple-
mentation progress, and where appropriate, refer the
provider to the study program support assistant for spe-
cific guidance on LG use (Table 2).
LG providers from sites that are not responsive to REP
initially and randomized to receive REP + EF/IF will alsobe contacted by the EF, and the study team will also con-
tact the site to identify an IF at the time of randomization.
The IF will be an individual supervising the LG provider
in some capacity. In this arm, LG providers will have regu-
lar calls with the EF and IF, as well as meet with IF one on
one on a regular basis. As with the REP + EF arm, EFs will
identify the individual strengths of each LG provider and
help leverage those strengths with available influence the
LG provider has at the site. In addition, the IF at each site
will meet with the LG provider and will use their internal
knowledge of the site to help the LG provider identify op-
portunities to align LG program goals with existing site
priorities (Table 2). Sites randomized to receive IF will re-
ceive up to $5,500 to cover IF-related time.
Ensuring fidelity to implementation strategies
Fidelity monitoring will be used to assess whether each
site is receiving the core components of each implemen-
tation strategy (REP, EF, and IF) and to ensure that there
is no contamination across roles. Data from LG provider
logs and EF/IF activities completed by study staff will be
used to ascertain fidelity within each 6-month period
of implementation strategy exposure using established
checklists. All sites will get the same LG REP package,
and LG training will be conducted by the study trainer
who will hold regional trainings in each state. The EF
will be trained by study investigators based on a 2-day
training program developed for national roll-out of both
the REP and EF/IF programs.
Fidelity to REP is defined based on number of sites re-
ceiving an LG package, number of providers completing
the 1-day LG training program, and number of com-
pleted lists of patients receiving LG. Fidelity to the EF
role will be defined using the following criteria based on
the components outlined in Table 2: 1) number of com-
pleted calls by the EF with LG providers at each site; 2)
number of documented barriers, facilitators, and specific
measurable goals to LG uptake; and 3) documentation
of LG provider strengths and available opportunities to
influence site activities and overcome barriers. Fidelity to
the IF role is defined as 1) number of meetings with the
LG provider and EF, 2) number of meetings IF and LG
provider have with site leadership, 3) number of docu-
mented opportunities to leverage LG uptake with exist-
ing site priority goals, and 4) development of a strategic
plan to implement LG by the IF.
Primary outcomes and measures
Study staff members (not site employees) will collect
patient and provider data to ensure consistency of out-
comes data collection over time. Outcomes assessors
will be blinded to implementation condition. The assess-
ment package previously implemented by study investi-
gators was informed by the RE-AIM framework for
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used in routine clinical care [75,76]. Key measures include
patient-level outcomes, LG fidelity, organizational factors,
and REP, EF, and IF activities [49,77-79].
Patient data collection
Lists of patients and contact information that were iden-
tified by the LG providers during pre-randomization
will be sent to study staff members who will conduct
independent clinical assessments. As the study is focused
on implementation processes for an evidence-based treat-
ment that does not involve randomizing at the patient
level, local institutional review boards (IRBs) considered
the protocol to not fall under research, and no patient in-
formed consent is required for the clinical assessments.
Staff members will contact patients and describe the pur-
pose of the phone-based clinical assessment, which will be
conducted at baseline, 6, 12, 18, and 24 months later.
The clinical assessment will include previously estab-
lished measures used in routine care, including the SF-
12 for MH-QOL [80] (primary outcome), the Patient
Health Questionnaire (PHQ-9) for mood symptoms
[81,82], the World Health Organization Disability As-
sessment Scale (WHO-DAS) for functional impairment
[83,84], GAD-7 for anxiety symptoms [85], and the In-
ternal State Scale for manic symptoms [86,87] (second-
ary and exploratory outcomes). Additional information
[44,88-91] including participant demographics will also
be ascertained from the clinical assessment during each
follow-up period.
Provider and organizational surveys
Study staff members will survey providers from the par-
ticipating sites, including the site clinical director and
LG providers on organizational factors that might im-
pact implementation and outcomes. As the study’s prin-
cipal institutional review board (University of Michigan
Medical School Institutional Review Board - IRBMED)
considered this study to fall under quality improvement
activities, no informed consent is required from pro-
viders or clinic directors. Clinic directors will be con-
tacted prior to the initiation of the REP in-service to
complete an initial site organizational survey [43,44] that
includes questions on resources, staff turnover, and inte-
grated care [92]. A longitudinal organizational assessment
will also be given to the clinic directors and LG providers
prior to the initiation of REP, then again at 12 and
24 months later to assess changes in organizational fea-
tures that might be impacted by REP and Facilitation. The
assessment includes two established questionnaires fo-
cused on organizational capacity to implement EBPs. The
Implementation Leadership Scale (ILS) assesses the degree
of organizational support for EBPs, and the Implementa-
tion Climate Scale (ICS) assesses staff ’s impressions onexpectations and support for effective EBP implementa-
tion through their policies, procedure, and behaviors [93].
Life goals fidelity
Because this study is designed to assess real-world im-
plementation, minimally invasive measures to assess LG
fidelity will be based on provider logs sent via a secure
web-based form to study staff on a weekly basis. Study
staff members will also collect confirmatory data from
patient surveys on receipt of LG sessions at the patient
level. The fidelity monitor calculates a total score based
on number of sessions completed by each patient and
the percentage completing five of six sessions. Average
patient completion of sessions of ≥75% was associated
with improved mental health-related quality of life [49].
Secondary aims: facilitation implementation and costs
Data on the implementation of EF and EF/IF will be col-
lected by study staff members using previously estab-
lished assessments for monitoring implementation
activities [40,43,94]. Study staff members will interview
LG providers, EF, IF, and site clinic leaders regarding
barriers and facilitators to LG, REP, and EF/IF strategies,
interactions between the EF and IFs, and specific strat-
egies EFs and IFs use to facilitate LG uptake across dif-
ferent sites.
Implementation strategy costs will be ascertained by
the study staff members based on study staff logs of REP
activities, and LG provider and EF and IF logs based on
a standardized list of activity categories (Table 3). EF
and IF time is likely to account for the vast majority of
costs associated with the implementation strategies, in-
cluding site employees (LG provider time on training
and LG implementation, IF time at meetings) as well as
project staff (REP package development, training/program
assistance, EF Facilitator time in site follow-ups). All costs
will be multiplied by personnel wage rates including fringe.
Patient-level costs will also be estimated from self-reported
utilization survey data on inpatient, ER, and outpatient
use. Costs will be assigned using Current Procedural Ter-
minology (CPT) codes, and a relative value unit (RVU)
weight will allow us to use the Medicare Fee Schedule to
calculate a standardized cost in US dollars for each service,
adjusted for annual levels of inflation using the consumer
price index.
Analyses
Intent to treat analyses will be performed. The primary
analysis will compare interventions in non-responding
sites beginning with REP + EF/IF versus interventions
beginning with REP + EF on longitudinal patient-level
change in number of LG sessions received, SF-12 mental
health-related quality of life scores, and PHQ-9 scores.
This analysis is a two-sample comparison of cells A + B
Table 3 Summary of specific implementation strategy
activities
Implementation
component
Tasks
REP Pre-implementation meetings with study
staff and consultants to finalize
implementation design
Study staff finalize plans for data security
and related research logistics
Creation of LG website for use by providers
(software development, programming)
Creation of packaged, user-friendly manual
and customized training program
Conduct organizational needs assessment
at sites
Pre-implementation in-service meetings
with site leaders
Identify LG providers at each site
Identify potential Internal Facilitators (IF)
at each site
Regional 8-h LG trainings
As-needed program support assistance
via phone or email
Monitor LG uptake via secure web-based
reporting
Disseminate monthly implementation
progress reports to all sites
Sites that are non-responsive are
randomized to receive External Facilitation
(EF) alone or EF + IF in combination
Send out quarterly program updates that
include bright spots and success stories
for overcoming barriers in implementation.
External Facilitation (EF) Weekly phone calls with facilitators and
technical assistance staff to transfer
knowledge and strengthen partnership
EF contacts LG provider/s at non-responsive
sites at least monthly for 6 months to
develop rapport and understanding of site
Assist LG providers in identifying what
specific actions they can take to
implement program
Works with LG provider to set measurable
goals for site implementation and monitors
progress to support uptake
Provides specific guidance on overcoming
barriers in implementing LG components by
aligning LG’s strengths with LG’s available
influence at the site
Facilitators refer LG providers to existing
resources including ongoing LG program
assistance when necessary
Weekly meetings or calls between EF and
TA to ensure open communication and
collaboration
Facilitator weekly consultation meeting
with facilitation experts
Table 3 Summary of specific implementation strategy
activities (Continued)
Internal Facilitation (IF) EF contacts IF at site to provide overview of
internal facilitation role and documentation
requirements for 6 month period
IF, EF, and LG hold biweekly calls to develop
rapport, review program progress and identify
barriers and facilitators to LG uptake
IF works with LG provider to develop
measurable goals to LG uptake.
IF identifies local site priorities per leadership
that align with LG program.
IF helps LG provider identify other LG
program champions.
EF helps IF and LG provider summarize and
describe added value of LG to leadership
and site providers (e.g., consistency with
other initiatives, support from leadership)
IF refers LG provider to LG program
assistance as needed and appropriate
IF, EF, and LG provider summarize progress
and present to leadership
IF works with EF and LG provider to develop
business and sustainability plans and presents
to leadership
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dinal outcomes will be measured at months 6 (pre-
randomization), 12, 18, and 24. The primary contrast is
the between groups difference in change from month 6
to month 18. The follow-up contrast at month 24 will
also be examined in this and all subsequent analyses.
The primary aim analysis for health-related quality of
life (the primary longitudinal outcome) will use linear
mixed models (LMM; [95]), also known as random effects
models. The unit of analysis is the individual patient
within a site (recall that approximately 20 individuals will
be identified prior to randomization). LMMs use all avail-
able measurements, allowing individuals to have an un-
equal number of longitudinal observations and producing
unbiased parameter estimates as long as unobserved
values are missing at random. The analysis will fit a three-
level (repeated measures for each individual clustered
within site) LMM with fixed effects for the intercept, time,
group, and a group-by-time interaction term, where group
is an indicator of REP + EF/IF vs. REP + EF. The LMM will
include random effects for site and time, an unstructured
within-person correlation structure for the residual errors,
and it will adjust for state and type of practice (primary
care or mental health site). LMMs similar to the above will
be conducted for the secondary patient-level outcomes:
change in number of LG sessions received, functional im-
pairment, and mood symptoms.
Secondary aim analyses will be conducted to deter-
mine whether continuing REP + EF vs. augmenting with
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who are non-responsive to REP + EF at month 12.
This secondary analysis is a comparison of cells B vs. C
(Figure 2). Outcomes will be examined using an LMM
similar to that described above, except (a) including
only the subset of sites that do not respond at month 12
to REP + EF, (b) using monthly longitudinal outcomes
from month 12 to month 24, and (c) the LMM will use
dummy indicators for time (i.e., time-saturated model
since there are only three measurement times for each
longitudinal outcome). The longitudinal course of discon-
tinuing REP + EF (or REP + EF/IF) will also be examined
at month 12 among sites that are responsive at month 12.
Other secondary aim analyses include comparison of
EF and EF + IF costs over time using a standardized list
of REP and EF/IF activities (Table 3), as well as assess-
ment of organizational change over time [96]. Additional
exploratory analyses will also compare the different
adaptive interventions embedded in the SMART design
(Figure 2) in terms of changes in longitudinal outcomes
using methods based on Robins and colleagues [97,98].
Missing values may occur in outcomes due to dropout
or inability to reach patients for follow-up (anticipated
10% attrition). A thorough investigation of mechanisms
for missing data will be carried out and will be dealt with
using multiple imputation procedures [99]. In stability
analyses, data will be analyzed with and without the
multiple imputation strategy. Any discrepancies will be
reported and carefully examined.
Sample size and power
The estimated sample size for this study is based on a
comparison of between groups (REP + EF/IF versus REP +
EF) in changes in the most conservative effect size estimate
(mental health-related quality of life scores) between
month 6 and month 18 (Cohen’s D = .23). This is a two-
sample comparison of patients within sites in cells A + B +
C versus D + E (Figure 2). To account for the between-site
variation induced by the within-site correlation in quality
of life outcomes, we inflate the variance term in the stand-
ard sample size formula by 1 + (n − 1) × ICC, where ICC is
the site inter-class correlation coefficient for the SF-12
mental health-related quality of life component score.
Based on our previous randomized controlled implementa-
tion trial [40,43], the site ICC was estimated at .01. Using a
two-sided, two-sample t test, a Type I error rate of 5%, and
with 60 sites (30 sites randomized to REP + EF/IF versus
30 sites randomized to REP + EF) and 16 patients per site
after accounting for attrition, we will have 94% power
to detect clinically significant changes in quality of life
scores, assuming an ICC= .01. Based on previous data,
with SD = 8.35 for the MH-QOL component score, this ef-
fect size corresponds to being able to detect a clinically
meaningful difference of at least 4 units in MH-QOL score.Trial status
Sites will be identified and participation confirmed by
October 2014. Site training and REP procedures will
begin in the fall of 2014. A timeline of implementation
activities is provided in Table 3.
Discussion
To date, this will be one of the largest randomized con-
trolled trials to develop a site-level adaptive implementa-
tion strategy. This is also one of the first studies to test the
augmentation of an established implementation strategy
(REP) using REP + EF/IF or REP + EF alone among sites
that exhibit non-response after 6 months. This study will
determine whether augmentation of the implementation
strategy is needed (e.g., REP + EF/IF) or whether in some
circumstances withholding augmentation may result in a
delayed implementation effect of REP + EF alone among
non-responsive sites. Second, this study will utilize a novel
SMART design developed by the study investigators [51]
to accomplish this implementation trial. SMARTs allow
efficient comparison of the overall impact of receiving dif-
ferent intervention augmentation strategies over time and
incremental costs of one intervention strategy over an-
other in improved outcomes among non-responsive sites.
In addition, this design allows the potential to determine
the added value of implementation strategies applied to
real-world treatment settings.
There is a paucity of research on effective implementa-
tion strategy that improves EBP uptake and ultimately
patient outcomes, notably in smaller, community-based,
safety net practices, which serve a substantial proportion
of patients with mood disorders. There have been few
rigorous trials of implementation strategy to promote
the uptake of EBPs in community-based practices [1,35].
Previous implementation studies have focused on highly
organized practices such as the VA or staff-model HMOs
and mainly involved intensive implementation strategy that
might not be feasible to apply to smaller, lower-resourced
practices. Among the frameworks that guide implementa-
tion efforts (e.g., [100]), few have been operationalized suf-
ficiently to enable community-based practices to enhance
EBP uptake.
Adaptive Implementation of Effective Programs Trial
(ADEPT) represents a growing cadre of rigorous yet real-
world trials that involve site-level randomization of quality
improvement strategies to augment the implementation of
evidence-based practices. Specifically, informed consent
from participants is not required per the recommendation
of the IRB because the focus of ADEPT is on the use of im-
plementation strategies at the site level, above and beyond
available resources to disseminate effective programs, in
order to assist existing providers in adopting an evidence-
based practice. Moreover, the delivery of the evidence-
based practice to patients is not altered or controlled at the
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includes measures that are used across many of the
practice settings as part of routine clinical care. These
types of studies have high generalizability to real-world
settings because they reflect the pragmatic strategies
needed to improve healthcare delivery and foster learn-
ing health systems [101,102]. ADEPT evaluates the use
of an evidence-based intervention (i.e., life goals) that is
superior to usual care from the patient perspective
while testing an implementation strategy (facilitation)
that is beneficial to providers and practices by improv-
ing their ability to adopt such evidence-based practices
[102]. Designation as a QI trial does not remove IRB
regulatory oversight but instead reduces the burden on
researchers (costs) and patients (time) to participate in
written informed consent and formal survey assessment
meetings which do not reflect real-world care but in-
stead introduce potential patient selection biases that
undermine patient participation in the intervention
[101,102].
REP uses key tactical strategies that can promote effect-
ive EBP adoption in community-based providers. How-
ever, these providers may face multiple organizational
barriers at their sites including competing demands or
lack of experience in garnering leadership buy-in that are
beyond the scope of toolkit dissemination, structured
training, or initial performance feedback [10,15,16,103].
Addressing these barriers may require strategic thinking
and multilevel organizational alliances [104,105] that en-
gage providers in supporting and owning the implementa-
tion [106-108]. While leadership support in EBP adoption
is important [109-111], involvement and buy-in from
frontline providers are also crucial to EBP sustainability
[94,109,112-118]. Hence, REP may need to be augmented
to address these organizational barriers to adoption
[119,120] and to ultimately show value of the EBP through
the triple aim (improving patient outcomes, experience,
lowering costs) [121].
Our study will determine the added value of augment-
ing implementation programs through Facilitation on
EBP uptake, sustainability, and patient outcomes, ultim-
ately determining the public health impact of implemen-
tation strategies for persons with mental disorders. Akin
to stepped treatment for patients, adaptive SMART de-
signs provide a tailored and potentially cost-effective
approach to augmenting standard implementation pro-
grams based on the specific needs of a site. This ap-
proach is needed to better understand how to improve
EBP uptake and patient mental health outcomes using
Facilitation, whereby REP is augmented given early signs
of site non-response. While REP might be sufficient for
some sites in adopting EBPs, our preliminary studies and
prior research [122,123] suggest that the majority will
need additional assistance. Moreover, sites initially notresponding to REP (i.e., limited adoption of EBPs) were
unlikely to do so in the future. IF is more expensive for
sites to implement, as the additional customization and
relationship building across individual sites due to varia-
tions in culture, climate, and capacity can be time con-
suming [113]. It is also unclear how long Facilitation is
needed to achieve its effect [103,109,117]. Adaptive in-
terventions involving REP and augmentation through
Facilitation are needed to determine the added value of
REP + EF/IF on improved patient outcomes, how long
Facilitation need to be continued to achieve outcomes,
and the cost-effectiveness of REP + EF/IF.
While this study has a number of strengths, including
the use of a novel implementation study design within
community-based practices, there are key limitations
that need to be considered. First, there is the potential
for self-selection of site early adopters which can limit
generalizability. The involvement of sites most willing to
participate in studies is inevitable with any implementa-
tion design. We have mitigated this potential selection
effect by inviting all sites from networks of practices
through state associations from across the country. In
addition, LG uptake and fidelity measures do not include
direct observations of sessions. In order to conduct an
implementation trial that reflected real-world consider-
ations, we chose to use indirect methods to measure LG
uptake, and cost considerations precluded us from con-
ducting in-person observations. Nonetheless, because
the study was considered non-regulated (non-research),
there is potential for increased generalizability especially
if patient dropout is minimized because they will be
assessed as part of routine clinical care. In addition, there
is a chance for contamination between the EF and IF
implementation strategies, especially if a less engaged IF
might promote the EF to become more active in assisting
the LG provider in identifying barriers and facilitators to
program uptake. Finally, not all sites from each state par-
ticipated, and those what are enrolled may not be repre-
sentative of community-based practices nationwide.
Conclusions
The results of this study will inform the implementation
of evidence-based practices across sites in two states, as
well as how to conduct practical implementation studies
in real-world healthcare settings. This study also sets the
stage for determining the added value of more intensive
implementation strategies within sites that need add-
itional support to promote the uptake of EBPs. Ultim-
ately, adaptive implementation strategies may produce
more relevant, rapid, and generalizable results by more
quickly validating or rejecting new implementation strat-
egies, thus enhancing the efficiency and sustainability of
implementation research and potentially lead to the roll-
out of more cost-efficient implementation strategies.
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